Vytulta was one of the main reasons that Valeant bought Bausch+Lomb for $8.7 billion in 2013, and the company had originally hoped to get it on the market in the first half of last year.

There have been rumours for several months that Bausch Health (formerly Valeant Pharmaceuticals), B+L's debt-ridden parent company, which retains an 88% ownership stake in its business ...

Growth Drivers: Factors fueling market expansion include the growing geriatric demographic, governmental attention to eye care policies, escalating diabetes rates globally, enhanced access to ...

GSK will also gain the rights to Valeant's back-up compounds that target potassium channels. Valeant receives an upfront payment of $125 million, and will share up to 50% of net profits on ...

The anti-aging market has witnessed exponential growth in recent years, with increasing consumer demand for innovative ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Der Dividenden-Chartvergleich zeigt die Rendite inklusive der Ausschüttungen (Aktienkurs + Dividende, grün) im Vergleich zum Aktienkurs (blau) und so die wirkliche Rendite einer Investition in ...